Nausheen Akhter, MD | Authors

Lausanne

1003

Articles

Cardiovascular Toxicity of Biologic Agents for Cancer Therapy

June 15, 2014

This review will focus on newer FDA-approved targeted therapies associated with type II chemotherapy-related cardiac dysfunction, or generally reversible cardiotoxicity, and will provide the latest information on the incidence and clinical spectrum of cardiotoxicity associated with each therapy, modifiable risk factors where known, and the mechanisms of cardiotoxicity.